Are You Getting the Drug You Were Prescribed?

By Josh Bloom —
It's common practice for your pharmacy to substitute a generic version of a drug for its brand counterpart. But another cost-saving policy is being considered: substituting an entirely different drug from the same class as what was prescribed. This is a terrible idea, as Dr. Robert Popovian explains.
Popovian Dr. Robert Popovian

 

Robert Popovian, Pharm.D., MS., who is the senior director of U.S. Government Relations at Pfizer, just wrote about something that you probably don't know, and at the same time it's also pretty scary. And it is also a terrible idea, designed to save money on prescription drugs while undoubtedly harming patients. In his latest op-ed entitled "No Substitute for Better Study to Protect Patients," Popovian, who is as dead-on knowledgeable about the pharmaceutical universe as anyone you'll meet, raises a real concern: A proposed change that would allow pharmacy benefit providers to substitute a different drug from the one on the prescription. And, this is not simply using a less expensive generic version of a drug, but rather, it is using a different drug in the same class. This is wrong on so many levels. "Therapeutic substitution should not be confused with generic substitution," Dr. Popovian explains. "Unlike therapeutic substitutions, generic substitutions involve drugs with the same active ingredients as determined by the FDA (or the equivalent government agency) as well as strength and dosage form that are therapeutically equivalent to the brand name drug." And, he adds, the consequences of such a policy are obvious. "These switched medicines contain a different active ingredient or, in some cases, a different delivery mechanism; which may lead to important differences in the medicine’s safety, efficacy and outcomes, and even uses that may be contrary to the indications approved by the Food and Drug Administration." You can read Dr. Popovian's op-ed in its entirety here.

Subscribe to our newsletter

Josh Bloom

Dr. Jonathan (Josh) Bloom, ACSH's Director of Chemical and Pharmaceutical Sciences, earned his Ph.D. at the University of Virginia and completed postdoctoral training at the University of Pennsylvania. During his 20-plus years in drug discovery at Wyeth, his research group discovered the antibiotic Tygacil®, approved in 2005. He holds 25 issued patents and has authored 35 academic papers. Since joining ACSH in 2010, he has written more than 2,000 articles and dozens of op-eds for major newspapers, including The Wall Street Journal and Chicago Tribune.

Recent articles by this author: